Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jinsy A Andrews

Showing results (1-10 of 33) with videos related to

Pageof 4
Sort By:
Handbook of Clinical Neurology|July 17, 2019
Clinical neurophysiology of anterior horn cell disordersJinsy A Andrews, Jeremy M Shefner
Neurology|June 8, 2019
ALS drug development guidances and trial guidelines: Consensus and opportunities for alignmentJinsy A Andrews, Lucie I Bruijn, Jeremy M Shefner
Current Opinion in Neurology|September 2, 2020
Amyotrophic lateral sclerosis: update on clinical managementSimone P Norris, Marie-France N Likanje, Jinsy A Andrews
Muscle & Nerve|November 29, 2025
Startle Reflex in Primary Lateral Sclerosis (PLS): A Comparison With Amyotrophic Lateral Sclerosis (ALS)Grace E Jang, Ikjae Lee, Jinsy A Andrews, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|August 16, 2021
Medical therapies for amyotrophic lateral sclerosis-related respiratory decline: an appraisal of needs, opportunities and obstaclesCarolyn Young, Susana Pinto, Julian Grosskreutz, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|March 17, 2016
A randomized, placebo-controlled, double-blind phase IIb trial evaluating the safety and efficacy of tirasemtiv in patients with amyotrophic lateral sclerosisJeremy M Shefner, Andrew A Wolff, Lisa Meng, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|June 24, 2020
Real-world evidence of riluzole effectiveness in treating amyotrophic lateral sclerosisJinsy A Andrews, Carlayne E Jackson, Terry D Heiman-Patterson, et al.
Neurology and Therapy|March 3, 2026
Exploring the Lived Experiences of Individuals with Amyotrophic Lateral Sclerosis (ALS): A Qualitative Study and Conceptual Model of Signs, Symptoms, and Functional ImpactsWilliam B Nowell, Nadine McGale, Oren Levy, et al.
Muscle & Nerve|November 19, 2017
CK-2127107 amplifies skeletal muscle response to nerve activation in humansJinsy A Andrews, Timothy M Miller, Vipin Vijayakumar, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|February 7, 2018
VITALITY-ALS, a phase III trial of tirasemtiv, a selective fast skeletal muscle troponin activator, as a potential treatment for patients with amyotrophic lateral sclerosis: study design and baseline characteristicsJinsy A Andrews, Merit E Cudkowicz, Orla Hardiman, et al.
Pageof 4

Showing results (1-10 of 33) with videos related to

Sort By:
Pageof 4
Handbook of Clinical Neurology|July 17, 2019
Clinical neurophysiology of anterior horn cell disordersJinsy A Andrews, Jeremy M Shefner
Neurology|June 8, 2019
ALS drug development guidances and trial guidelines: Consensus and opportunities for alignmentJinsy A Andrews, Lucie I Bruijn, Jeremy M Shefner
Current Opinion in Neurology|September 2, 2020
Amyotrophic lateral sclerosis: update on clinical managementSimone P Norris, Marie-France N Likanje, Jinsy A Andrews
Muscle & Nerve|November 29, 2025
Startle Reflex in Primary Lateral Sclerosis (PLS): A Comparison With Amyotrophic Lateral Sclerosis (ALS)Grace E Jang, Ikjae Lee, Jinsy A Andrews, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|August 16, 2021
Medical therapies for amyotrophic lateral sclerosis-related respiratory decline: an appraisal of needs, opportunities and obstaclesCarolyn Young, Susana Pinto, Julian Grosskreutz, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|March 17, 2016
A randomized, placebo-controlled, double-blind phase IIb trial evaluating the safety and efficacy of tirasemtiv in patients with amyotrophic lateral sclerosisJeremy M Shefner, Andrew A Wolff, Lisa Meng, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|June 24, 2020
Real-world evidence of riluzole effectiveness in treating amyotrophic lateral sclerosisJinsy A Andrews, Carlayne E Jackson, Terry D Heiman-Patterson, et al.
Neurology and Therapy|March 3, 2026
Exploring the Lived Experiences of Individuals with Amyotrophic Lateral Sclerosis (ALS): A Qualitative Study and Conceptual Model of Signs, Symptoms, and Functional ImpactsWilliam B Nowell, Nadine McGale, Oren Levy, et al.
Muscle & Nerve|November 19, 2017
CK-2127107 amplifies skeletal muscle response to nerve activation in humansJinsy A Andrews, Timothy M Miller, Vipin Vijayakumar, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|February 7, 2018
VITALITY-ALS, a phase III trial of tirasemtiv, a selective fast skeletal muscle troponin activator, as a potential treatment for patients with amyotrophic lateral sclerosis: study design and baseline characteristicsJinsy A Andrews, Merit E Cudkowicz, Orla Hardiman, et al.
Pageof 4